Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587785 | 0.85 | NPC1 (0.39) | NPC1RAB9AHTTRECQLPPARG | |
| SCHEMBL13933546 | 0.82 | NTRK1 (0.37) | NPC1RAB9APPARGPYGLNTRK1 | |
| SCHEMBL14587626 | 0.82 | POLB (0.45) | NPC1RAB9AHTTRECQLPPARG | |
| SCHEMBL14587786 | 0.82 | NPC1 (0.44) | NPC1RAB9AHTTRECQLPPARG | |
| SCHEMBL14587621 | 0.81 | NPC1 (0.39) | NPC1RAB9AHTTRECQLPPARG | |
| SCHEMBL3828418 | 0.81 | NTRK1 (0.37) | NPC1RAB9APPARGPYGLNTRK1 | |
| SCHEMBL14297687 | 0.81 | NPC1 (0.41) | NPC1RAB9AHTTRECQLPPARG | |
| SCHEMBL14587694 | 0.81 | RAB9A (0.56) | NPC1RAB9AHTTRECQLPPARG | |
| SCHEMBL14587693 | 0.81 | RAB9A (0.46) | NPC1RAB9AHTTRECQLPPARG | |
| SCHEMBL5010908 | 0.81 | PPARG (0.44) | NPC1RAB9AHTTRECQLPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | NPC1 2838/4885RAB9A 2748/4885HTT 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.